Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Home

Main sub menu

  • Investors
  • Careers
    • Working at Recipharm
    • The Recipharm story
    • Meet our employees
    • Current vacancies
  • Contact
    • Contact us
    • Development services contacts
    • Manufacturing services contacts
    • Locations
      • France
        • Fontaine
        • Kaysersberg
        • Monts
        • Pessac
      • Germany
        • Monheim
        • Wasserburg
        • Zwickau
      • India
        • Bengaluru
        • Karnal / Paonta Sahib
      • Israel
        • Ness Ziona
      • Italy
        • Brescia
        • Lainate
        • Masate
        • Paderno Dugnano
        • Pianezza
      • Portugal
        • Odivelas
        • Queluz
      • Spain
        • Parets
        • Leganés
      • Sweden
        • Höganäs
        • Stockholm city (HQ)
        • Karlskoga
        • Solna
        • Strängnäs
        • Uppsala
        • Uppsala Development
      • UK
        • Cramlington
        • Holmes Chapel
        • Queenborough
        • King’s Lynn
      • USA
        • Research Triangle Park

Main navigation

  • Development
    • Drug substance
    • Drug product
    • Analytical chemistry
    • Clinical trial material (CTM)
  • Manufacturing
    • Solids
    • Semi-solids
    • Liquids
    • Inhalation
    • Injectables
    • Ophthalmics
  • Solutions
    • Recipharm Analytical Solutions™
    • Recipharm Inhalation Solutions™
    • Recipharm Pathway to Clinic®
    • Serialisation
  • Bespak
  • Learn
  • Press & events
    • Press
    • Events
    • Reports
    • Insights
  • Our story
    • Recipharm in brief
    • Business model
    • Sustainability
    • Company history

Press & events

What's happening?

Stay updated on our latest news and events.

Press and Event

  • Press
  • Events
  • Reports
  • Insights
Displaying 1 - 10 of 44

Subscribe

Press

Announcement of prospectus regarding the admission to trading of new shares in Recipharm issued in connection with the acquisition of Lusomedicamenta

2014.12.22 Read more

Press

Customer to transfer Swedish penicillin manufacturing

2014.12.04 Read more

Press

Recipharm completes acquisition of Flamel Technologies facility in France

2014.12.01 Read more

Press

Change in the total number of shares and votes in Recipharm AB (publ)

2014.11.28 Read more

Press

Recipharm acquires Flamel Technologies facility and extend development services in France

2014.11.27 Read more

Press

Recipharm sponsors award for best doctoral thesis

2014.11.19 Read more

Press

Invitation to telephone conference due to Recipharm’s acquisition of Lusomedicamenta

2014.11.14 Read more

Press

Recipharm acquires Lusomedicamenta for SEK 1 billion

2014.11.13 Read more

Press

Interim report January-September 2014

2014.11.07 Read more

Press

Interim report January-September 2014

2014.11.07 Read more

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page Next ›
  • Last page Last »

Footer menu

  • Privacy policy
  • Cookies
  • Website terms
© 2021 Recipharm AB (publ). All rights reserved Stormfors Digitalbyrå